Search
Triheptanoin
go.drugbank.com/drugs/DB11677ApprovedInvestigationalTriheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. … [A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.
Galcanezumab
go.drugbank.com/drugs/DB14042ApprovedInvestigational[A33105] Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsRopinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIn 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease.
Categories: Nonergot-derivative Dopamine Receptor AgonistsDiosmin
go.drugbank.com/drugs/DB08995ApprovedInvestigationalChronic venous insufficiency is a common condition the western population. … Diosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.[A232890,T840,L33040]
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalSilodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder … [L32368] Most commonly affecting males over the age of 40 years, benign prostatic hyperplasia is the non-malignant enlargement of the prostate gland, associated with lower urinary tract symptoms that have
Categories: Adrenergic alpha-1 Receptor AntagonistsAcalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalexpected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. … the therapeutic uses of acalabrutinib [L1009].
Calaspargase pegol
go.drugbank.com/drugs/DB14730ApprovedInvestigationalSC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], [A40270]. … Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) [A40270].
Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigational[L15316, L15321] Under the EUA granted in February 2021, bamlanivimab is used in combination with [etesevimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk … [A224044, L20974] It is set to enter phase 3 clinical trials.
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnMobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). … 1.5- to 10-fold lower than those required to inhibit wild-type EGFR.
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsCantharidin
go.drugbank.com/drugs/DB12328ApprovedInvestigational[A32891, A32892] For its natural purpose, the male blister beetle secretes and presents the cantharidin to a female beetle as a copulatory gift during mating. … Cantharidin is a naturally occurring odorless, colorless fatty substance of the terpenoid class that is produced as an oral fluid in the alimentary canal of the male blister beetle.